Joseph Payne, Arcturus CEO (Arcturus via YouTube)
CSL stacks up $4.5B in chips — with a $200M ante — to wager on the next-gen mRNA wave
Australian pharma giant CSL is making a late bid for mRNA glory, and they’ve lined up one of the also-ran US Covid-19 biotechs touting their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
